Tagged with GIC

pharma The founder and managing director of LT Clinical Research, one of the first wholly black-owned South African CRO, reveals how South Africa is a very conducive environment for CROs, with a diverse patient population, a well-established regulatory framework and a currency that compares well to other African currencies; why the…

pharma Jörg Buck, the Executive Director of the Italian-German Chamber of Commerce discusses the close trade relationship which ties the two countries together, how the business environment in Italy is evolving today and the need to keep the momentum in the economic recovery. To start off, having joined the chamber recently,…

Pharma The owner of Altis Biologics, Nick Duneas, illustrates the significance of the company’s flagship product, the Altis Osteogenic Bone Matrix (OBM) and how the company plans to commercialize the injectable bone graft substitute on a domestic and international scale moving forward. He also highlights how the Innovation Prize for Africa has…

pharma  Pfizer Global Established Products’ BU Head and  Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well as the challenges faced by the French biosimilars market and what Pfizer-Hospira is doing to achieve the huge potential in…

pharma Ozgur Tomruk, J&J’s Managing Director for Global Surgery talks about Turkey’s importance for the company, the priorities they have set, J&J’s commitment to quality and his ambition for the company’s future in Turkey. As an introduction for our readers, Ozgur, can you please give an overview of where J&J Turkey…

strategic levels Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also describes how the company’s new reagent facility in Germany will help bolster it domestically and regionally. Can you tell us…

Interface Biologics Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation and the advantages of collaborating with international partners. You joined IBI in 2008, what was your initial mandate upon arriving here? My initial mandate was to demonstrate commercial viability. Since…

GCB Mr. Lin, you enjoyed a decades-long career in the ICT industry before making the transition to healthcare. What can you tell our readers about the evolution of General Biologics Corp. under your leadership? GBC was established in 1984. Government shareholders held 70 percent ownership, with the remaining 30 percent distributed…

P&G Singapore Innovation Center (SgIC) Why did P&G decide to set up the center in Singapore? There are several reasons why P&G decided on Singapore. First, we wanted to reach more consumers, particularly in emerging markets; Singapore is very central to that. From Singapore we can reach 2/3 of the world’s population within a 6…

Hoya Surgical Optics Please give us an overview of HOYA Surgical Optics and its operations. HOYA Surgical Optics is a global manufacturer of intraocular lenses (IOLs) — the artificial lens that is put in the eye during cataract surgery when the natural lens clouds over with age and needs to be surgically removed.…

Cegedim Strategic Data Malaysia Nowadays we can talk of an abundance of information coming from companies like Frost& Sullivan, IMS and even consultancies who are producing their own data. As a leader in market research how can CSD find a space within this picture and what strategies does it employ to stay ahead of…

Office for the Strategic Coordination of Health Research (OSCHR) It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some examples of the new way forward. According to you, what are the factors that drove Government to pursue such drastic…